Immunotherapy developer Hookipa, backed by Gilead, Boehringer Ingelheim and Takeda, has collected $37.5m in a series D round led by Redmile Group.
Hookipa Pharma, an Austria-based immunotherapy developer that counts pharmaceutical companies Gilead Sciences, Boehringer Ingelheim and Takeda as shareholders, yesterday completed a $37.5m series D round.
Redmile Group led the round that featured investment firms Invus and Samsara BioCapital, as well as several unnamed existing investors.
Hookipa is developing immunotherapies that are designed to reprogram the body’s immune system to treat infectious diseases and cancer.
The company’s arenavirus platform engineers viruses to deliver disease-specific proteins called antigens. The immune system is able to…
